Better Therapeutics- Tradeable Rights - March 2021 Total Revenue

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) currently reports a total revenue of $0 as of September 2023. That compares with $280K in the prior-year period — down 100.0% year over year. That is below the sector sector average of $1.3B. Use the charts on this page to explore Better Therapeutics- Tradeable Rights - March 2021's total revenue history and peer comparisons.

Better Therapeutics- Tradeable Rights - March 2021's total revenue decreased from $280K to $0 — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Better Therapeutics- Tradeable Rights - March 2021's total revenue of $0 is lower than the its sector sector average of $1.3B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Better Therapeutics- Tradeable Rights - March 2021 reported $0 in total revenue as of September 2023. That compares with $280K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.3B. From there, open related valuation or income-statement pages for Better Therapeutics- Tradeable Rights - March 2021, and consider following MCADR for alerts when major investors trade the stock.